252 related articles for article (PubMed ID: 19422646)
1. Plasma IL-6, its soluble receptors and F2-isoprostanes at rest and during exercise in chronic fatigue syndrome.
Robinson M; Gray SR; Watson MS; Kennedy G; Hill A; Belch JJ; Nimmo MA
Scand J Med Sci Sports; 2010 Apr; 20(2):282-90. PubMed ID: 19422646
[TBL] [Abstract][Full Text] [Related]
2. Response of plasma IL-6 and its soluble receptors during submaximal exercise to fatigue in sedentary middle-aged men.
Gray SR; Robinson M; Nimmo MA
Cell Stress Chaperones; 2008; 13(2):247-51. PubMed ID: 18320358
[TBL] [Abstract][Full Text] [Related]
3. The effect of exercise on plasma soluble IL-6 receptor concentration: a dichotomous response.
Robson-Ansley P; Cockburn E; Walshe I; Stevenson E; Nimmo M
Exerc Immunol Rev; 2010; 16():56-76. PubMed ID: 20839491
[TBL] [Abstract][Full Text] [Related]
4. Release of interleukin-6 and its soluble receptors by activated peripheral blood monocytes is elevated in hypocholesterolemic hemodialysis patients.
Tsirpanlis G; Chatzipanagiotou S; Boufidou F; Kordinas V; Alevyzaki F; Zoga M; Kyritsis I; Ioannou D; Fatourou A; Nicolaou C
Am J Nephrol; 2005; 25(5):484-90. PubMed ID: 16127269
[TBL] [Abstract][Full Text] [Related]
5. The effect of repeated endurance exercise on IL-6 and sIL-6R and their relationship with sensations of fatigue at rest.
Robson-Ansley P; Barwood M; Canavan J; Hack S; Eglin C; Davey S; Hewitt J; Hull J; Ansley L
Cytokine; 2009 Feb; 45(2):111-6. PubMed ID: 19097916
[TBL] [Abstract][Full Text] [Related]
6. Circulating interleukin 6 and soluble forms of its receptors in relation to resting energy expenditure in women with anorexia nervosa.
Karczewska-Kupczewska M; Adamska A; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
Clin Endocrinol (Oxf); 2013 Dec; 79(6):812-6. PubMed ID: 23199226
[TBL] [Abstract][Full Text] [Related]
7. [Determination of serum soluble interleukin-6 receptor and soluble gp130 levels in patient with pregnancy induced hypertension and its significance].
Li Y; Wang Y; Qi L
Zhonghua Fu Chan Ke Za Zhi; 2001 Jan; 36(1):18-9. PubMed ID: 11778537
[TBL] [Abstract][Full Text] [Related]
8. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
9. Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness.
Weiss TW; Arnesen H; Seljeflot I
Metabolism; 2013 Jul; 62(7):1008-13. PubMed ID: 23428306
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection.
Migita K; Abiru S; Maeda Y; Daikoku M; Ohata K; Nakamura M; Komori A; Yano K; Yatsuhashi H; Eguchi K; Ishibashi H
Hum Immunol; 2006; 67(1-2):27-32. PubMed ID: 16698422
[TBL] [Abstract][Full Text] [Related]
11. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
Aparicio-Siegmund S; Garbers Y; Flynn CM; Waetzig GH; Gouni-Berthold I; Krone W; Berthold HK; Laudes M; Rose-John S; Garbers C
Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E411-E420. PubMed ID: 31237452
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
[TBL] [Abstract][Full Text] [Related]
13. [Examination and evaluation of sIL-6R, sgp130 in serum in patients with chronic hepatopathy].
Shang J; Xu Y; Zhang H
Zhonghua Gan Zang Bing Za Zhi; 2000 Apr; 8(2):87-8. PubMed ID: 10861111
[TBL] [Abstract][Full Text] [Related]
14. In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD.
Memoli B; Grandaliano G; Soccio M; Postiglione L; Guida B; Bisesti V; Esposito P; Procino A; Marrone D; Michael A; Andreucci M; Schena FP; Pertosa G
J Am Soc Nephrol; 2005 Apr; 16(4):1099-107. PubMed ID: 15716332
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
Nagaoka T; Sato S; Hasegawa M; Ihn H; Takehara K
J Rheumatol; 2000 Aug; 27(8):1917-21. PubMed ID: 10955333
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.
Pulsatelli L; Boiardi L; Pignotti E; Dolzani P; Silvestri T; Macchioni P; Cantini F; Salvarani C; Facchini A; Meliconi R
Arthritis Rheum; 2008 Aug; 59(8):1147-54. PubMed ID: 18668607
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum.
Gaillard J; Pugnière M; Tresca J; Mani J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Sep; 10(3):337-44. PubMed ID: 10477390
[TBL] [Abstract][Full Text] [Related]
18. Chronic fatigue syndrome: new evidence for a central fatigue disorder.
Georgiades E; Behan WM; Kilduff LP; Hadjicharalambous M; Mackie EE; Wilson J; Ward SA; Pitsiladis YP
Clin Sci (Lond); 2003 Aug; 105(2):213-8. PubMed ID: 12708966
[TBL] [Abstract][Full Text] [Related]
19. Prefrontal cortex oxygenation during incremental exercise in chronic fatigue syndrome.
Patrick Neary J; Roberts AD; Leavins N; Harrison MF; Croll JC; Sexsmith JR
Clin Physiol Funct Imaging; 2008 Nov; 28(6):364-72. PubMed ID: 18671793
[TBL] [Abstract][Full Text] [Related]
20. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder.
Mehra R; Storfer-Isser A; Kirchner HL; Johnson N; Jenny N; Tracy RP; Redline S
Arch Intern Med; 2006 Sep; 166(16):1725-31. PubMed ID: 16983050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
